We are analyzing https://link.springer.com/article/10.1186/bcr1982.

Title:
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy | Breast Cancer Research
Description:
Introduction The phenotypic and functional differences between cells that initiate human breast tumors (cancer stem cells) and those that comprise the tumor bulk are difficult to study using only primary tumor tissue. We embarked on this study hypothesizing that breast cancer cell lines would contain analogous hierarchical differentiation programs to those found in primary breast tumors. Methods Eight human breast cell lines (human mammary epithelial cells, and MCF10A, MCF7, SUM149, SUM159, SUM1315 and MDA.MB.231 cells) were analyzed using flow cytometry for CD44, CD24, and epithelial-specific antigen (ESA) expression. Limiting dilution orthotopic injections were used to evaluate tumor initiation, while serial colony-forming unit, reconstitution and tumorsphere assays were performed to assess self-renewal and differentiation. Pulse-chase bromodeoxyuridine (5-bromo-2-deoxyuridine [BrdU]) labeling was used to examine cell cycle and label-retention of cancer stem cells. Cells were treated with paclitaxol and 5-fluorouracil to test selective resistance to chemotherapy, and gene expression profile after chemotherapy were examined. Results The percentage of CD44+/CD24- cells within cell lines does not correlate with tumorigenicity, but as few as 100 cells can form tumors when sorted for CD44+/CD24-/low/ESA+. Furthermore, CD44+/CD24-/ESA+ cells can self-renew, reconstitute the parental cell line, retain BrdU label, and preferentially survive chemotherapy. Conclusion These data validate the use of cancer cell lines as models for the development and testing of novel therapeutics aimed at eradicating cancer stem cells.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Telecommunications
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,542,081 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cells, cell, cancer, sum, lines, breast, cdcdesa, figure, line, article, brdu, pubmed, human, tumors, scholar, google, stem, esa, tumor, flow, sorted, primary, days, file, cultures, cas, cytometry, data, cdcd, cdcdlowesa, tumorigenic, additional, label, exhibit, percentage, chemotherapy, mdamb, expression, basal, phenotype, mammary, epithelial, luminal, stemlike, tissue, similar, populations, res, parental, cellular,

Topics {✒️}

cd44+/cd24-/esa+breast cancer stem cd44+/cd24-/low/epithelial-specific antigen cd44+/cd24-/low/esa+ sorted cells cd44+/cd24-/low/esa+ subpopulation cd44+/cd24-/esa+ stem cells cd44+/cd24-/esa+ cells ranges generate cd44+/cd24+/esa+ cells viable cd44+/cd24-/esa+ cells target cd44+/cd24-/esa+ cells cd44+/cd24-/low/esa+ cells cd44+cd24-esa+ phenotype enriches cd44+/cd24-/low/esa+ subpopulations cd44+/cd24-/low/esa+ phenotype [2] cd44+/cd24-/low/esa+ fraction cd44+/cd24-/esa+cells cycle cd44+/cd24-/esa- sorted cells cd44+/cd24+/esa+ sorted cells sorted cd44+/cd24-/esa+ cells cd44+/cd24+/esa+ cells exhibited cd44+/cd24-/esa- colonies exhibited cd44+/cd24-/esa+ cells detected cd44+/cd24-/esa- populations formed cd44+/cd24-/low phenotype enrich stem/progenitor cell properties cd44+/cd24-/esa- basal cells characterize stem/progenitor cells cd44+/cd24-/low/esa+ 000 cd44+/cd24-/low/esa+ 000 cd44+/cd24-/low/esa cd44+cd24-esa+ subpopulation super-low adherence plates article download pdf cd44+/cd24-/low cells breast cancer-initiating cells fluorescence-activated cell sorting cd44+/cd24-/esa- fractions cd44+/cd24+/esa+ fractions high-resolution genomic profiles cd44+/cd24-cells associates stem-cell biology stem cell biology label-retaining epithelial cells cd44+/cd24-/esa+ cells cd44+/cd24-/esa- cells cd44+/cd24+/esa+ cells cd44+/cd24-//esa- cells cd44+/cd24-/esa+cells 30% cd44+/cd24-/esa+ cells cd44+/cd24-/esa+ sorted cancer-derived cell lines

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
         description:The phenotypic and functional differences between cells that initiate human breast tumors (cancer stem cells) and those that comprise the tumor bulk are difficult to study using only primary tumor tissue. We embarked on this study hypothesizing that breast cancer cell lines would contain analogous hierarchical differentiation programs to those found in primary breast tumors. Eight human breast cell lines (human mammary epithelial cells, and MCF10A, MCF7, SUM149, SUM159, SUM1315 and MDA.MB.231 cells) were analyzed using flow cytometry for CD44, CD24, and epithelial-specific antigen (ESA) expression. Limiting dilution orthotopic injections were used to evaluate tumor initiation, while serial colony-forming unit, reconstitution and tumorsphere assays were performed to assess self-renewal and differentiation. Pulse-chase bromodeoxyuridine (5-bromo-2-deoxyuridine [BrdU]) labeling was used to examine cell cycle and label-retention of cancer stem cells. Cells were treated with paclitaxol and 5-fluorouracil to test selective resistance to chemotherapy, and gene expression profile after chemotherapy were examined. The percentage of CD44+/CD24- cells within cell lines does not correlate with tumorigenicity, but as few as 100 cells can form tumors when sorted for CD44+/CD24-/low/ESA+. Furthermore, CD44+/CD24-/ESA+ cells can self-renew, reconstitute the parental cell line, retain BrdU label, and preferentially survive chemotherapy. These data validate the use of cancer cell lines as models for the development and testing of novel therapeutics aimed at eradicating cancer stem cells.
         datePublished:2008-03-26T00:00:00Z
         dateModified:2008-03-26T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr1982
         keywords:
            Breast Cancer Cell Line
            Cancer Stem Cell
            Parental Cell Line
            Human Mammary Epithelial Cell
            BrdU Label
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig6_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig7_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Christine M Fillmore
               affiliation:
                     name:Tufts University School of Medicine
                     address:
                        name:Department of Genetics, Sackler School, Tufts University School of Medicine, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Charlotte Kuperwasser
               affiliation:
                     name:Tufts University School of Medicine
                     address:
                        name:Department of Anatomy & Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, USA
                        type:PostalAddress
                     type:Organization
                     name:Tufts-New England Medical Center, Molecular Oncology Research Institute
                     address:
                        name:Department of Radiation Oncology, Tufts-New England Medical Center, Molecular Oncology Research Institute, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
      description:The phenotypic and functional differences between cells that initiate human breast tumors (cancer stem cells) and those that comprise the tumor bulk are difficult to study using only primary tumor tissue. We embarked on this study hypothesizing that breast cancer cell lines would contain analogous hierarchical differentiation programs to those found in primary breast tumors. Eight human breast cell lines (human mammary epithelial cells, and MCF10A, MCF7, SUM149, SUM159, SUM1315 and MDA.MB.231 cells) were analyzed using flow cytometry for CD44, CD24, and epithelial-specific antigen (ESA) expression. Limiting dilution orthotopic injections were used to evaluate tumor initiation, while serial colony-forming unit, reconstitution and tumorsphere assays were performed to assess self-renewal and differentiation. Pulse-chase bromodeoxyuridine (5-bromo-2-deoxyuridine [BrdU]) labeling was used to examine cell cycle and label-retention of cancer stem cells. Cells were treated with paclitaxol and 5-fluorouracil to test selective resistance to chemotherapy, and gene expression profile after chemotherapy were examined. The percentage of CD44+/CD24- cells within cell lines does not correlate with tumorigenicity, but as few as 100 cells can form tumors when sorted for CD44+/CD24-/low/ESA+. Furthermore, CD44+/CD24-/ESA+ cells can self-renew, reconstitute the parental cell line, retain BrdU label, and preferentially survive chemotherapy. These data validate the use of cancer cell lines as models for the development and testing of novel therapeutics aimed at eradicating cancer stem cells.
      datePublished:2008-03-26T00:00:00Z
      dateModified:2008-03-26T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr1982
      keywords:
         Breast Cancer Cell Line
         Cancer Stem Cell
         Parental Cell Line
         Human Mammary Epithelial Cell
         BrdU Label
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig6_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1982/MediaObjects/13058_2007_Article_1946_Fig7_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Christine M Fillmore
            affiliation:
                  name:Tufts University School of Medicine
                  address:
                     name:Department of Genetics, Sackler School, Tufts University School of Medicine, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Charlotte Kuperwasser
            affiliation:
                  name:Tufts University School of Medicine
                  address:
                     name:Department of Anatomy & Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, USA
                     type:PostalAddress
                  type:Organization
                  name:Tufts-New England Medical Center, Molecular Oncology Research Institute
                  address:
                     name:Department of Radiation Oncology, Tufts-New England Medical Center, Molecular Oncology Research Institute, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:10
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Tufts University School of Medicine
      address:
         name:Department of Genetics, Sackler School, Tufts University School of Medicine, Boston, USA
         type:PostalAddress
      name:Tufts University School of Medicine
      address:
         name:Department of Anatomy & Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, USA
         type:PostalAddress
      name:Tufts-New England Medical Center, Molecular Oncology Research Institute
      address:
         name:Department of Radiation Oncology, Tufts-New England Medical Center, Molecular Oncology Research Institute, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Christine M Fillmore
      affiliation:
            name:Tufts University School of Medicine
            address:
               name:Department of Genetics, Sackler School, Tufts University School of Medicine, Boston, USA
               type:PostalAddress
            type:Organization
      name:Charlotte Kuperwasser
      affiliation:
            name:Tufts University School of Medicine
            address:
               name:Department of Anatomy & Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, USA
               type:PostalAddress
            type:Organization
            name:Tufts-New England Medical Center, Molecular Oncology Research Institute
            address:
               name:Department of Radiation Oncology, Tufts-New England Medical Center, Molecular Oncology Research Institute, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Genetics, Sackler School, Tufts University School of Medicine, Boston, USA
      name:Department of Anatomy & Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, USA
      name:Department of Radiation Oncology, Tufts-New England Medical Center, Molecular Oncology Research Institute, Boston, USA

External Links {🔗}(147)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.56s.

LINK . SPRINGER . COM {}